Supernus Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 652
- Market Cap
- $1.9B
- Website
- http://www.supernus.com
- Introduction
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
- Conditions
- Interventions
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 272
- Registration Number
- NCT04099667
- Locations
- 🇺🇸
Nova Clinical Research, LLC, Bradenton, Florida, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Rancho Research Institute, Downey, California, United States
Therapy for Migraine Prevention in Children 6-11 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04050293
- Locations
- 🇺🇸
CNS Healthcare, Memphis, Tennessee, United States
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
- Conditions
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT04016779
- Locations
- 🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸Princeton Medical Institute, Princeton, New Jersey, United States
🇺🇸Gulfcoast Research Center, Fort Myers, Florida, United States
Classroom Study of SPN-812 in Children With ADHD
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Registration Number
- NCT04016792
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT03944785
- Locations
- 🇺🇸
Hartford Healthcare, Vernon, Connecticut, United States
🇺🇸Southeast Neuroscience Center, LLC, Gray, Louisiana, United States
🇺🇸NYU Winthrop Hospital, Mineola, New York, United States
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03638466
- Locations
- 🇺🇸
Florida Clinical Research Center, LLC., Maitland, Florida, United States
🇺🇸University of South Florida- Dept. of Psychiatry and Neurosciences, Tampa, Florida, United States
🇺🇸Meridien Research aka Florida Clinical Research Center, LLC, Lakeland, Florida, United States
Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors
- Conditions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03615703
- Locations
- 🇺🇸
Meridien Research, Inc., Orlando, Florida, United States
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
- Conditions
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03597503
- Locations
- 🇺🇸
iResearch Atlanta, Decatur, Georgia, United States
🇺🇸Hassmann Research Institute, Berlin, New Jersey, United States
🇺🇸Family Psychiatry of the Woodlands, The Woodlands, Texas, United States
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures
- Conditions
- Interventions
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03474770
- Locations
- 🇦🇺
The Royal Melbourne Hospital, Melbourne, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Supernus Pharmaceuticals, Inc.
- Target Recruit Count
- 297
- Registration Number
- NCT03247556
- Locations
- 🇺🇸
Alliance for Wellness dba Alliance for Research, Long Beach, California, United States
🇺🇸Meridien Research at Florida Clinical Research Center, Bradenton, Florida, United States
🇺🇸Miami Clinical Research, Miami, Florida, United States